Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency... see more

TSX:MBX - Post Discussion

Microbix Biosystems Inc > Unimpressive short piece, but still something
View:
Post by yielddude on Jan 02, 2025 9:43am

Unimpressive short piece, but still something

This "Simpy Wall Street" which pumps out voluminous "stuff" every day. But still, decent summary for any newbie to get started at looking at the company

Overview: Microbix Biosystems Inc. is a life science company that develops and commercializes proprietary biological and technological solutions for human health across North America, Europe, and internationally, with a market cap of CA$55.59 million.

Operations: The company's revenue is primarily derived from its Antigens, QAPs, and DxTM segment, which generated CA$21.31 million.
 

Market Cap: CA$55.59M

Microbix Biosystems Inc., with a market cap of CA$55.59 million, has demonstrated significant revenue growth, reporting CA$25.39 million for the fiscal year ended September 2024, up from CA$16.51 million the previous year. The company has become profitable, posting a net income of CA$3.52 million compared to a loss in the prior year. Its financial health is bolstered by short-term assets exceeding liabilities and more cash than debt, with interest well covered by EBIT (16.7x). Recent strategic alliances and regulatory achievements in Europe further position Microbix for continued growth across its business lines.

https://finance.yahoo.com/news/discover-3-tsx-penny-stocks-141235244.html
 

 
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities